Trial · NCT03511105
Results by group206
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 206
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Baseline Adjusted Total Protein Concentration in Broncho-alveolar (BAL) Samples at 24 Hours After Segmental LPS Challenge (26 Hours Post-first Dose) | Placebo | 348.46 | 95% Confidence Interval 285.97 to 425.67 | Milligrams per liter | |
| Baseline Adjusted Total Protein Concentration in Broncho-alveolar (BAL) Samples at 24 Hours After Segmental LPS Challenge (26 Hours Post-first Dose) | GSK2798745 | 318.43 | 95% Confidence Interval 260.18 to 389.98 | Milligrams per liter | |
| Baseline Adjusted Total Cell Count of Neutrophils in BAL Samples at 24 Hours After Segmental LPS Challenge (26 Hours Post-first Dose) | Placebo | 58.94 | 95% Confidence Interval 42.70 to 81.42 | 10^6 cells per milliliter | |
| Baseline Adjusted Total Cell Count of Neutrophils in BAL Samples at 24 Hours After Segmental LPS Challenge (26 Hours Post-first Dose) | GSK2798745 | 54.63 | 95% Confidence Interval 39.21 to 75.90 | 10^6 cells per milliliter | |
| Baseline Adjusted Differential Cell Count of Neutrophils in BAL Samples at 24 Hours After Segmental LPS Challenge (26 Hours Post-first Dose) | Placebo | 58.57 | 95% Confidence Interval 54.37 to 63.09 | Percentage of total cell count | |
| Baseline Adjusted Differential Cell Count of Neutrophils in BAL Samples at 24 Hours After Segmental LPS Challenge (26 Hours Post-first Dose) | GSK2798745 | 58.54 | 95% Confidence Interval 54.22 to 63.12 | Percentage of total cell count | |
| Number of Participants Reporting Serious Adverse Events (SAEs) and Non-SAEs | Placebo | Any SAE | 0 | Participants | |
| Number of Participants Reporting Serious Adverse Events (SAEs) and Non-SAEs | GSK2798745 | Any SAE | 0 | Participants | |
| Number of Participants Reporting Serious Adverse Events (SAEs) and Non-SAEs | Placebo | Any non-SAE | 10 | Participants | |
| Number of Participants Reporting Serious Adverse Events (SAEs) and Non-SAEs | GSK2798745 | Any non-SAE | 7 | Participants | |
| Change From Baseline Values for Clinical Chemistry Parameters | Placebo | ALP, Day 2 | 1.64 | Standard Deviation 8.144 | International units per liter |
| Change From Baseline Values for Clinical Chemistry Parameters | GSK2798745 | ALP, Day 2 | 4.00 | Standard Deviation 7.578 | International units per liter |
| Change From Baseline Values for Clinical Chemistry Parameters | Placebo | ALP, Day 9 | -3.20 | Standard Deviation 7.953 | International units per liter |
| Change From Baseline Values for Clinical Chemistry Parameters | GSK2798745 | ALP, Day 9 | -1.86 | Standard Deviation 6.198 | International units per liter |
| Change From Baseline Values for Clinical Chemistry Parameters | Placebo | ALT, Day 2 | 1.2 | Standard Deviation 16.87 | International units per liter |
| Change From Baseline Values for Clinical Chemistry Parameters | GSK2798745 | ALT, Day 2 | -3.5 | Standard Deviation 3.08 | International units per liter |
| Change From Baseline Values for Clinical Chemistry Parameters | Placebo | ALT, Day 9 | 4.4 | Standard Deviation 26.94 | International units per liter |
| Change From Baseline Values for Clinical Chemistry Parameters | GSK2798745 | ALT, Day 9 | -2.6 | Standard Deviation 5.14 | International units per liter |
| Change From Baseline Values for Clinical Chemistry Parameters | Placebo | AST, Day 2 | 18.4 | Standard Deviation 109.78 | International units per liter |
| Change From Baseline Values for Clinical Chemistry Parameters | GSK2798745 | AST, Day 2 | -2.3 | Standard Deviation 3.97 | International units per liter |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03511105/results